WuXi Biologics Deepens Japan Ties as Complex Biologics Demand Surges

Event summary

  • WuXi Biologics hosted its third CRDMO Day in Tokyo on May 20, 2026, focusing on biologics innovation from IND to commercialization.
  • Over 50% of WuXi Biologics' projects are now complex modalities, with bispecific/multi-specific antibodies and ADCs growing by nearly 30% annually.
  • The company has passed 46 regulatory inspections by the end of 2025, including 22 by the U.S. FDA and EU EMA.
  • WuXi Biologics exhibited at the 28th Interphex Week, Japan's largest pharmaceutical and biotechnology trade show.

The big picture

WuXi Biologics is positioning itself as a critical partner for Japan's biopharmaceutical innovation, particularly in complex modalities. The company's global platform and regulatory track record underscore its strategic advantage in a market increasingly focused on advanced biologics. With over 945 integrated client projects and a growing emphasis on sustainability, WuXi Biologics is shaping the future of biologics development and manufacturing.

What we're watching

Market Positioning
Whether WuXi Biologics can sustain its leadership in complex modalities as Japan's biopharmaceutical industry evolves.
Regulatory Dynamics
The pace at which WuXi Biologics can maintain regulatory compliance across its global footprint.
Strategic Investments
How WuXi Biologics' long-term investments in capabilities and talent will impact its competitive edge.